Mark P. Smith

1.7k total citations
48 papers, 1.2k citations indexed

About

Mark P. Smith is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Mark P. Smith has authored 48 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 9 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Mark P. Smith's work include Hemophilia Treatment and Research (23 papers), Platelet Disorders and Treatments (16 papers) and Blood Coagulation and Thrombosis Mechanisms (14 papers). Mark P. Smith is often cited by papers focused on Hemophilia Treatment and Research (23 papers), Platelet Disorders and Treatments (16 papers) and Blood Coagulation and Thrombosis Mechanisms (14 papers). Mark P. Smith collaborates with scholars based in New Zealand, United Kingdom and United States. Mark P. Smith's co-authors include Geoffrey F. Savidge, Peter M. George, Gary Moore, J. Bonnar, Lucy Norris, Philip Steer, Christopher A. Ludlam, Andrew D. Laurie, Elisabeth M. Cramer and Anwar Alhaq and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Blood.

In The Last Decade

Mark P. Smith

48 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark P. Smith New Zealand 23 822 229 220 123 111 48 1.2k
Carlo L. Balduini Italy 20 674 0.8× 181 0.8× 248 1.1× 99 0.8× 60 0.5× 52 1.1k
Silvia Linari Italy 22 1.3k 1.5× 205 0.9× 388 1.8× 97 0.8× 68 0.6× 75 1.7k
Wim Terpstra Netherlands 18 542 0.7× 317 1.4× 183 0.8× 65 0.5× 115 1.0× 36 1.0k
Guillermo J. Ruiz‐Delgado Mexico 17 616 0.7× 180 0.8× 203 0.9× 59 0.5× 55 0.5× 130 953
Nicholas Wickham Australia 16 292 0.4× 256 1.1× 174 0.8× 53 0.4× 95 0.9× 35 804
Anaadriana Zakarija United States 15 348 0.4× 157 0.7× 252 1.1× 96 0.8× 158 1.4× 29 790
Steven Andrèsen United States 16 417 0.5× 211 0.9× 138 0.6× 40 0.3× 68 0.6× 48 915
Orhan Ayyıldız Türkiye 16 324 0.4× 93 0.4× 179 0.8× 62 0.5× 22 0.2× 64 657
Berthold Hoppe Germany 17 242 0.3× 110 0.5× 86 0.4× 56 0.5× 41 0.4× 50 705
Ann B. Zimrin United States 17 327 0.4× 255 1.1× 96 0.4× 39 0.3× 21 0.2× 45 1.3k

Countries citing papers authored by Mark P. Smith

Since Specialization
Citations

This map shows the geographic impact of Mark P. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark P. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark P. Smith more than expected).

Fields of papers citing papers by Mark P. Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark P. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark P. Smith. The network helps show where Mark P. Smith may publish in the future.

Co-authorship network of co-authors of Mark P. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Mark P. Smith. A scholar is included among the top collaborators of Mark P. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark P. Smith. Mark P. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
John, M. Joseph, Philip Kuriakose, Mark P. Smith, Eve Roman, & Sudhir Tauro. (2021). The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challenges. Blood Cancer Journal. 11(8). 141–141. 2 indexed citations
2.
Smith, Mark P., et al.. (2011). Diagnosis ofvon Willebrand Disease in South Island, New Zealand. Seminars in Thrombosis and Hemostasis. 37(5). 555–559. 1 indexed citations
3.
Sheen, Campbell R., et al.. (2011). Genotyping the factor VIII intron 22 inversion locus using fluorescent in situ hybridization. Blood Cells Molecules and Diseases. 46(2). 151–158. 1 indexed citations
4.
5.
6.
Smith, Mark P., Robert Klamroth, P.M. Mannucci, et al.. (2007). ReFacto®1 and Advate®2: a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia. 13(2). 124–130. 39 indexed citations
7.
Laurie, Andrew D., et al.. (2007). The molecular aetiology of haemophilia A in a New Zealand patient group. Haemophilia. 13(4). 420–427. 13 indexed citations
8.
Smith, Mark P., Lucy Norris, Philip Steer, Geoffrey F. Savidge, & J. Bonnar. (2004). Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. American Journal of Obstetrics and Gynecology. 190(2). 495–501. 71 indexed citations
9.
Mitchell, Michael, et al.. (2004). Germline mosaicism resulting in the transmission of severe hemophilia B from a grandfather with a mild deficiency. American Journal of Medical Genetics Part A. 129A(1). 13–15. 10 indexed citations
10.
Ludlam, Christopher A., Mark P. Smith, Massimo Morfini, et al.. (2003). A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. British Journal of Haematology. 120(5). 808–813. 65 indexed citations
11.
Moore, Gary, Mark P. Smith, & Geoffrey F. Savidge. (2003). The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants. Blood Coagulation & Fibrinolysis. 14(3). 307–312. 36 indexed citations
12.
13.
Ho, Aloysius, Susan E. Height, & Mark P. Smith. (2000). Immune Tolerance Therapy for Haemophilia. Drugs. 60(3). 547–554. 40 indexed citations
14.
Blay, Jean‐Yves, Ian Judson, Sjoerd Rodenhuis, et al.. (1999). Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Anti-Cancer Drugs. 10(10). 873–878. 13 indexed citations
15.
Alhaq, Anwar, Michael Mitchell, Salman Rahman, et al.. (1999). Identification of a novel mutation in a non‐Jewish factor XI deficient kindred. British Journal of Haematology. 104(1). 44–49. 24 indexed citations
16.
Mitchell, Michael, Simon R. Thompson, Gary Moore, et al.. (1999). Heterozygous factor XI deficiency associated with three novel mutations. British Journal of Haematology. 107(4). 763–765. 28 indexed citations
17.
Kazmi, M, et al.. (1998). Acquired haemophilia A. Blood Coagulation & Fibrinolysis. 9(7). 623–628. 26 indexed citations
18.
Smith, Mark P., Kevin M. Rice, Kaye Spence, et al.. (1997). Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease. Blood Coagulation & Fibrinolysis. 8(1). 6–12. 16 indexed citations
19.
Smith, Mark P., Elisabeth M. Cramer, & Geoffrey F. Savidge. (1997). 7 Megakaryocytes and platelets in α-granule disorders. Baillière s Clinical Haematology. 10(1). 125–148. 35 indexed citations
20.
Smith, Mark P., et al.. (1988). Physician assessments of practice patterns in emergency department radiograph interpretation. Annals of Emergency Medicine. 17(10). 1019–1023. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlo L. Balduini Breakdown of academic impact, for papers by Silvia Linari Breakdown of academic impact, for papers by Wim Terpstra Breakdown of academic impact, for papers by Guillermo J. Ruiz‐Delgado Breakdown of academic impact, for papers by Nicholas Wickham Breakdown of academic impact, for papers by Anaadriana Zakarija Breakdown of academic impact, for papers by Steven Andrèsen Breakdown of academic impact, for papers by Orhan Ayyıldız Breakdown of academic impact, for papers by Berthold Hoppe Breakdown of academic impact, for papers by Ann B. Zimrin
Rankless by CCL
2026